Healius Ltd (HLS)
Australian Securities Exchange · Australia · prices in AUD · close of 20 Oct 2026
Key indicators
| Last close | AUD 0.390 |
|---|---|
| 52-week range | 0.300 – 1.070 |
| Return, 1 month / 3 months | +4.0% / +11.4% |
| Return, 1 year / 3 years | −50.3% / −71.5% |
| Trend | Below its 200-day average |
| RSI (14) | 47 |
| Volatility (1 year) | 61.0% |
| Worst drawdown (1 year) | -69.7% |
| Average daily value traded | 2.13M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Healius is an Australian healthcare company that provides medical diagnostic services. It operates pathology laboratories and diagnostic imaging centres, offering tests and scans that doctors use to diagnose and monitor patients. The company also runs medical centres and related healthcare services. Its customers are mainly general practitioners, specialists, hospitals and patients across Australia, and it is based in Sydney.
Healius Ltd trades under the code HLS on the Australian Securities Exchange in Australia, with its price quoted in Australian dollars (AUD). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Healius Ltd (HLS) trades on the Australian Securities Exchange in Australia. It last closed at AUD 0.390 on 20 October 2026.
Its price-based Market X-Ray is 46 out of 100 (a weak price profile), ranking 1,011 of 1,815 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 50.3% and over the last three months it rose 11.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 28 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -24.4% | ||
| From 52-week high | -62.5% | ||
| Momentum | 45 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 11.4% | ||
| 6-month return | -26.4% | ||
| 12-month return, skipping the last month | -52.2% | ||
| Stability (higher is calmer) | 43 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 61.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -69.7% | ||
| Liquidity | 83 · Strong | Trades actively. | |
| Average daily value traded | 2.13M AUD | ||
| Zero-volume days | 1.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 2 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +1.3% |
|---|---|
| 1 month | +4.0% |
| 3 months | +11.4% |
| 6 months | −26.4% |
| 1 year | −50.3% |
| 3 years | −71.5% |
| 5 years | −88.0% |
Signals
| 50-day / 200-day average | 0.415 / 0.516 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.023 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 9 May 2025 | AUD 0.4130 |
| 7 Sep 2022 | AUD 0.0555 |
| 24 Mar 2022 | AUD 0.0926 |
| 13 Sep 2021 | AUD 0.0625 |
| 25 Mar 2021 | AUD 0.0602 |
| 26 Mar 2020 | AUD 0.0241 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.